U.S. Hereditary Angioedema Therapeutics Market Size & Outlook
U.S. hereditary angioedema therapeutics market, 2018-2030 (US$M)
Related Markets
U.S. hereditary angioedema therapeutics market highlights
- The U.S. hereditary angioedema therapeutics market generated a revenue of USD 1,030.4 million in 2023 and is expected to reach USD 2,047.2 million by 2030.
- The U.S. market is expected to grow at a CAGR of 10.3% from 2024 to 2030.
- In terms of segment, kallikrein inhibitor was the largest revenue generating treatment in 2023.
- Kallikrein inhibitor is the most lucrative treatment segment registering the fastest growth during the forecast period.
Hereditary angioedema therapeutics market data book summary
| Market revenue in 2023 | USD 1,030.4 million |
| Market revenue in 2030 | USD 2,047.2 million |
| Growth rate | 10.3% (CAGR from 2023 to 2030) |
| Largest segment | Kallikrein inhibitor |
| Fastest growing segment | Kallikrein inhibitor |
| Historical data | 2018 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | C1-esterase inhibitor, Bradykinin B2 receptor antagonist, Kallikrein inhibitor, Others Treatment |
| Key market players worldwide | BioCryst Pharmaceuticals Inc, Ionis Pharmaceuticals Inc, CSL Ltd, Adverum Biotechnologies Inc, KalVista Pharmaceuticals Inc, Takeda Pharmaceutical Co Ltd, Pharming Group, Attune Pharmaceuticals |
Other key industry trends
- In terms of revenue, U.S. accounted for 37.1% of the global hereditary angioedema therapeutics market in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In North America, U.S. hereditary angioedema therapeutics market is projected to lead the regional market in terms of revenue in 2030.
- Canada is the fastest growing regional market in North America and is projected to reach USD 228.0 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Hereditary Angioedema Therapeutics Market Scope
Hereditary Angioedema Therapeutics Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
U.S. hereditary angioedema therapeutics market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to hereditary angioedema therapeutics market will help companies and investors design strategic landscapes.
Kallikrein inhibitor was the largest segment with a revenue share of 44.72% in 2023. Horizon Databook has segmented the U.S. hereditary angioedema therapeutics market based on c1-esterase inhibitor, bradykinin b2 receptor antagonist, kallikrein inhibitor, others treatment covering the revenue growth of each sub-segment from 2018 to 2030.
High incidence of HAE, growing awareness about the disease, and availability of advanced pharmaceutical technologies are likely to propel the market in the country. Although the prevalence data is unclear, there are an estimated 15,000 to 30,000 emergency admissions for HAE episodes in the U.S. annually, and around 6,000 people are living with the condition.
The presence of private and public organizations focusing on the wellbeing of patients is further propelling the market. For instance, the U.S. Hereditary Angioedema Association is a nonprofit organization focusing on advancing research to benefit people suffering from HAE.
Furthermore, the presence of key market players and the introduction of technologically advanced are driving the country's market. For instance, in January 2021, Glenmark Pharmaceuticals announced the FDA approval of generic version of Firazyr (icatibant injection) for treatment of swelling attacks in HAE patients in the U.S.
Reasons to subscribe to U.S. hereditary angioedema therapeutics market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of U.S. hereditary angioedema therapeutics market databook
-
Our clientele includes a mix of hereditary angioedema therapeutics market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the U.S. hereditary angioedema therapeutics market, including forecasts for subscribers. This country databook contains high-level insights into U.S. hereditary angioedema therapeutics market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
U.S. hereditary angioedema hae therapeutics market size, by treatment, 2018-2030 (US$M)
U.S. Hereditary Angioedema Therapeutics Market Share, 2023 & 2030 (US$M)
Related industry reports
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
